Compare FuelCell Energy Inc (FCEL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs IDEXX Laboratories, Inc. — how do they compare? FuelCell Energy Inc trades at $17.66 (market cap $1.47B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 27.5× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FCEL | IDXX | |
|---|---|---|
Market Cap | $1.47B | $40.43B |
Volume | 12,559,948 | 692,164 |
Sector | Industrials | Health |
52-Week High | $36.01 | $766.68 |
52-Week Low | $6.00 | $504.70 |
Typical Hold Time | 48 Days | 46 Days |
Enterprise Value | $1.05B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL stock trades at $18.37, down 11.07% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $158.16M in 2025 but sustained a net loss of $187.90M, reflecting negative profit margins. Recent news highlights a securities class action lawsuit filed against the company, alleging disclosure failures between June and September 2026.
The outlook remains challenged by persistent losses and high cash burn, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include the class action litigation, execution on profitability, and reliance on financing activities to fund operations.
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
